As a strategy to be the leading company in the development of innovative diagnostic solutions, non-invasive, accurate and cost-effective, allowing enjoy better health, we are also working on the development of other algorithms MBDAA for other cancers taking advantage of the methodology and knowledge gained in the development of the algorithms for Lung Cancer, Ovarian Cancer, Prostate Cancer and Cancer of Unknown Primary.

In this sense we have 2 algorithms for Breast Cancer and Liver Cancer in phase 4 (phase in which the test is already developed) of the 5 phases that exist: Research; Assay Development; Testing; Validation of R&D; and Market Ready (CE Certification, among others).

Besides, we also have 3 algorithms for Bladder Cancer, Colorectal Cancer and Head & Neck Cancer in phase 2 (phase in which the test is in development).

Moreover, we have also working in Cervix Cancer, Gastric Cancer, Kidney Cancer, Pancreatic Cancer, Testicular Cancer, Thyroid Cancer and Uterine Cancer in phase 1 (phase of research and literature search on novel tumor markers related to these pathologies).